FDA approves Flonase Sensimist allergy relief
GSK Consumer Healthcare announced today that the U.S. Food and Drug Administration (FDA) has approved Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5 mcg spray) as an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies. Previously available by prescription as Veramyst, Flonase Sensimist is the latest Rx-to-OTC switch from GSK.
Flonase Sensimist helps block six allergic substances, providing non-drowsy, 24-hour relief of both nose- and eye-related allergy symptoms like itchy, watery eyes, nasal congestion, runny nose, itchy nose and sneezing.
There are roughly 50 million people in the United States who suffer from allergies,2 and, as a category leader, GSK continues to innovate to satisfy the needs of all allergy sufferers, said Amardeep Kahlon, Director of Marketing.
In the case of Flonase Sensimist, GSK is proud to offer an additional treatment option that not only provides more complete allergy symptom relief1 but also suits specific consumer preferences.
Additional key features of Flonase Sensimist include:
Nasal allergy relief indicated for adults and children ages 2 and older
Scent-free
Alcohol-free
Little or no drip.
Source: drugs.com
